Alrex (Loteprednol Etabonate)
Brand Names: Alrex
Methodology & AI Transparency ⓘ
Alrex (Loteprednol Etabonate) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Formulated with active moiety Loteprednol Etabonate (cross-referenced at /meds/loteprednol-etabonate) and registered by Bausch & Lomb Incorporated, Alrex operates as a prescription brand-name corticosteroid therapy (RxNorm 213262; NDC 24208-353).
- 2 Real-world patient consensus: Commercial Alrex monograph (2 mg/mL Suspension/ Drops) cross-indexed with generic Loteprednol Etabonate for therapeutic equivalence review.
- 3 Typical cash cost range: 30-day cash pricing ranges from $124.43 on Cost Plus Drugs to $329.74 walk-in retail (NADAC $57.8963/unit).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Alrex (Loteprednol Etabonate): nausea (8.4%), headache (7%), dizziness (5%).
Ask our AI Specialists anything about Alrex (Loteprednol Etabonate)
Alrex (Loteprednol Etabonate) Mechanism, CYP450 Pathways & DailyMed Monograph
Formulated with active moiety Loteprednol Etabonate (cross-referenced at /meds/loteprednol-etabonate) and registered by Bausch & Lomb Incorporated, Alrex operates as a prescription brand-name corticosteroid therapy (RxNorm 213262; NDC 24208-353). Under 2022-03-31 FDA labeling for 2 mg/mL Suspension/ Drops; 0.2% Bottle of Suspension, alrex: ophthalmic suspension is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
Bioactive Loteprednol Etabonate within Alrex governs corticosteroid target modulation with class-characteristic hepatorenal disposition. Commercialized across 2 mg/mL Suspension/ Drops; 0.2% Bottle of Suspension (registered by Bausch & Lomb Incorporated, SPL 2022-03-31), Alrex combines branded dosage-form consistency (NDC 24208-353) with transparent cash-pay comparisons spanning $124.43 to $329.74.
Systemic exposure to Alrex (Loteprednol Etabonate) reflects Oral fraction absorbed ranges from 52% to 64% (Alrex (Loteprednol Etabonate) 2) absorption kinetics and dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of alrex (loteprednol etabonate), sustaining receptor engagement across a Mean elimination half-life of 4 to 8 hours across adult Alrex (Loteprednol Etabonate) dosing half-life window (oral tmax achieved within 2 to 3 hours following alrex (loteprednol etabonate) ingestion response profile).
Dosing protocols (2 mg/mL Suspension/ Drops or 0.2% Bottle of Suspension) balance efficacy (81.00% patient satisfaction across 17 logs) against nausea (8.4% of reports), headache (7% of reports), fatigue (5.4% of reports), with strict avoidance in previous anaphylactoid or exfoliative reaction attributed to alrex (loteprednol etabonate); clinical scenarios where corticosteroid exposure from alrex (loteprednol etabonate) poses unacceptable risk.
Verify medication reconciliation lists so Alrex (Loteprednol Etabonate) is not inadvertently duplicated with another corticosteroid.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Alrex (Loteprednol Etabonate) dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Alrex (Loteprednol Etabonate)
- Clinical scenarios where corticosteroid exposure from Alrex (Loteprednol Etabonate) poses unacceptable risk
Logged Side-Effect Incidence (17 Reports)
Alrex (Loteprednol Etabonate) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Alrex (Loteprednol Etabonate))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Safety of KPI-121 Ophthalmic Suspension 0.25% in Patients With Dry Eye Disease: A KPI-121 ophthalmic suspension 0.25% seemed to be safe and well tolerated when dosed QID for 2 to 4 weeks in those DED subjects included in the 4 trials. Cornea • 2021-05-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 32826644 ↗ |
Alrex (Loteprednol Etabonate) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $57.8963/unit (~$1736.89/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $124.43 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $329.74 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 17 Anonymous DotMD Community Micro-Logs | $143.09 / mo | View logs ↓ |
Alrex (Loteprednol Etabonate) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Alrex (Loteprednol Etabonate) RxNorm Concept ID | 213262 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $57.8963 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $329.74 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $124.43 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 81.00% Worth It (17 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Alrex (Loteprednol Etabonate) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Alrex (Loteprednol Etabonate) integrating DailyMed SPL (2022-03-31), CMS NADAC ($57.8963/unit), and 17 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Alrex (Loteprednol Etabonate) community threads and patient logs by age, biological sex, dosage, and treatment duration.